CD274 and neoplasm: Deng et al. reported effective tumor control at primary tumor sites and non-irradiated distant tumors with durable T cell immunity, when combining anti-PD-L1 mAb with a single dose of 12 Gy or 20 Gy in breast (TUBO) and colon (MC38) cancer models, respectively [29].